GlassScriptPhysician profile
Jonathan J Sharpe
NPI 1992834337
$159,656.20
in general payments reported to CMS, 2019-2025
19 companies · $8,871 in 2025
The $8,871 reported for 2025 was more than what 95% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $16K · 2021: $26K · 2022: $21K · 2023: $55K · 2024: $12K · 2025: $8,871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $48K · Royalty Or License: $20K · Travel and Lodging: $6,387 · Food and Beverage: $799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $47,887.20 |
| Royalty Or License | $20,316.21 |
| Travel and Lodging | $6,386.79 |
| Food and Beverage | $798.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $95,807.01 | 2019-2024 | Prostep, Ortholoc 3di, Hoffmann |
| Novastep INC. | $44,797.74 | 2019-2025 | Airlock Centrolock, Centrolock Mis Bunion Correction, Peca Bunion Correction System |
| Wright Medical Technology, INC. | $9,652.36 | 2019-2020 | |
| Arthrex, INC. | $4,106.56 | 2019 | |
| Rock Medical Orthopedics, INC. | $3,077.31 | 2019-2021 | |
| Smith+Nephew, INC. | $1,445.40 | 2019-2025 | |
| Integra Lifesciences Corporation | $144.17 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Trilliant Surgical LLC. | $123.37 | 2022 | |
| Medline Industries LP | $98.60 | 2020 | |
| Horizon Therapeutics Plc | $97.79 | 2019-2023 | Krystexxa |
| Acumed LLC | $92.29 | 2021 | |
| Zimmer Biomet Holdings, INC. | $86.96 | 2019-2020 | |
| Nevro Corp. | $38.00 | 2023 | Senza |
| Pacira Pharmaceuticals Incorporated | $23.96 | 2019 | |
| Organogenesis INC. | $20.57 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18.24 | 2024 | Krystexxa |
| Merck Sharp & Dohme LLC | $14.99 | 2019 | |
| Arteriocyte Medical Systems, INC. | $10.88 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$200,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Sharpe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.